行情

LJPC

LJPC

Jolla制药
NASDAQ

实时行情|Nasdaq Last Sale

6.02
-0.03
-0.50%
盘后: 6.02 0 0.00% 16:27 11/15 EST
开盘
6.14
昨收
6.05
最高
6.45
最低
5.94
成交量
30.92万
成交额
--
52周最高
16.44
52周最低
5.01
市值
1.63亿
市盈率(TTM)
-1.0132
分时
5日
1月
3月
1年
5年

分析师评级

6位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

LJPC 新闻

  • 关厂风波肆起、显示屏遭质疑:三星能否靠5G绝地求生
  • 蓝鲸TMT.16分钟前
  • 约翰逊承诺结束令经济“陷入瘫痪”的英退不确定性
  • 新浪财经综合.26分钟前
  • 一周财经日历丨美团、拼多多财报出炉,阿里或于周三定价
  • 华盛通.32分钟前
  • 蔚来宣布奉玮出任CFO 后者曾任中金研究部董事总经理
  • 新浪科技.1小时前

更多

所属板块

生物技术和医学研究
+1.25%
制药与医学研究
+1.34%

热门股票

名称
价格
涨跌幅

LJPC 简况

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH). It has initiated a Phase III trial of LJPC-501 for the treatment of CRH, called the Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS) Phase III trial. LJPC-401 is its formulation of synthetic human hepcidin for the potential treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome. LJPC-30S is its next-generation gentamicin derivative program that is focused on therapeutics for the potential treatment of serious bacterial infections, as well as rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.
展开

Webull提供La Jolla Pharmaceutical Company的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。